Department of General Thoracic Surgery, Inselspital, Bern University Hospital, University of Bern, Murtenstrasse 28, 3008, Bern, Switzerland.
Department for BioMedical Research, University of Bern, Bern, Switzerland.
Cancer Immunol Immunother. 2023 Dec;72(12):4457-4470. doi: 10.1007/s00262-023-03542-z. Epub 2023 Oct 5.
The inducible Kras/p53 lung adenocarcinoma mouse model, which faithfully recapitulates human disease, is routinely initiated by the intratracheal instillation of a virus-based Cre recombinase delivery system. Handling virus-based delivery systems requires elevated biosafety levels, e.g., biosafety level 2 (BSL-2). However, in experimental animal research facilities, following exposure to viral vectors in a BSL-2 environment, rodents may not be reclassified to BSL-1 according to standard practice, preventing access to small animal micro-computed tomography (micro-CT) scanners that are typically housed in general access areas such as BSL-1 rooms. Therefore, our goal was to adapt the protocol so that the Cre-induced KP mouse model could be handled under BSL-1 conditions during the entire procedure.
The Kras-Lox-STOP-Lox-G12D/p53 flox/flox (KP)-based lung adenocarcinoma mouse model was activated by intratracheal instillation of either an adenoviral-based or a gutless, adeno-associated viral-based Cre delivery system. Tumor growth was monitored over time by micro-CT. We have successfully substituted the virus-based Cre delivery system with a commercially available, gutless, adeno-associated, Cre-expressing vector that allows the KP mouse model to be handled and imaged in a BSL-1 facility. By optimizing the anesthesia protocol and switching to a microscope-guided vector instillation procedure, productivity was increased and procedure-related complications were significantly reduced. In addition, repeated micro-CT analysis of individual animals allowed us to monitor tumor growth longitudinally, dramatically reducing the number of animals required per experiment. Finally, we documented the evolution of tumor volume for different doses, which revealed that individual tumor nodules induced by low-titer AAV-Cre transductions can be monitored over time by micro-CT.
Modifications to the anesthesia and instillation protocols increased the productivity of the original KP protocol. In addition, the switch to a gutless, adeno-associated, Cre-expressing vector allowed longitudinal monitoring of tumor growth under BSL-1 conditions, significantly reducing the number of animals required for an experiment, in line with the 3R principles.
可诱导的 Kras/p53 肺腺癌小鼠模型,能够忠实再现人类疾病,通常通过气管内滴注病毒基 Cre 重组酶传递系统来启动。处理病毒基传递系统需要提高生物安全水平,例如生物安全水平 2(BSL-2)。然而,在实验动物研究设施中,在 BSL-2 环境中接触病毒载体后,根据标准实践,啮齿动物可能不会重新分类为 BSL-1,从而无法使用通常位于 BSL-1 房间等一般进入区域的小动物微计算机断层扫描(micro-CT)扫描仪。因此,我们的目标是调整方案,以便在整个过程中,在 BSL-1 条件下处理 Cre 诱导的 KP 小鼠模型。
通过气管内滴注腺病毒基或无肠、腺相关病毒基 Cre 传递系统,激活基于 Kras-Lox-STOP-Lox-G12D/p53 flox/flox(KP)的肺腺癌小鼠模型。通过 micro-CT 随时间监测肿瘤生长。我们成功地用一种商业上可获得的、无肠、腺相关、Cre 表达载体替代了病毒基 Cre 传递系统,该载体允许在 BSL-1 设施中处理和成像 KP 小鼠模型。通过优化麻醉方案并切换到显微镜引导的载体灌输程序,提高了生产力,并显著减少了与程序相关的并发症。此外,对单个动物进行重复的 micro-CT 分析允许我们进行纵向监测肿瘤生长,从而大大减少了每个实验所需的动物数量。最后,我们记录了不同剂量下肿瘤体积的演变,结果表明,通过低滴度 AAV-Cre 转导诱导的单个肿瘤结节可以通过 micro-CT 随时间进行监测。
麻醉和灌输方案的修改提高了原始 KP 方案的生产力。此外,切换到无肠、腺相关、Cre 表达载体允许在 BSL-1 条件下进行肿瘤生长的纵向监测,显著减少了实验所需的动物数量,符合 3R 原则。